Cargando…

Assessment of the effectiveness and efficiency of the economic community of West African States Medicines Regulatory Harmonization initiative by the pharmaceutical industry

Background: Following the establishment of Economic Community of West African States Medicines Regulatory Harmonization (ECOWAS-MRH) initiative in 2017, it was considered timely to carry out an evaluation of the current status of the initiative’s operating model by the pharmaceutical industry users....

Descripción completa

Detalles Bibliográficos
Autores principales:	Owusu-Asante, Mercy, Darko, Delese Mimi, Walker, Stuart, Salek, Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203491/ https://www.ncbi.nlm.nih.gov/pubmed/37229251 http://dx.doi.org/10.3389/fphar.2023.1184108

Ejemplares similares

Assessment of the effectiveness and efficiency of the West Africa medicines regulatory harmonization initiative by the member countries
por: Owusu-Asante, Mercy, et al.
Publicado: (2022)

Evaluation of the Food and Drugs Authority, Ghana Regulatory Review Process: Challenges and Opportunities
por: Owusu-Asante, Mercy, et al.
Publicado: (2022)

The South African Regulatory System: Past, Present, and Future
por: Keyter, Andrea, et al.
Publicado: (2018)

Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement
por: Ngum, Nancy, et al.
Publicado: (2022)

South African Regulatory Authority: The Impact of Reliance on the Review Process Leading to Improved Patient Access
por: Keyter, Andrea, et al.
Publicado: (2021)

Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities
por: McAuslane, Neil, et al.
Publicado: (2023)

The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland
por: Keyter, Andrea, et al.
Publicado: (2019)

Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies' publicly available documents
por: Leong Wai Yeen, James, et al.
Publicado: (2014)

Evaluation of the Effectiveness and Efficiency of the East African Community Joint Assessment Procedure by Member Countries: The Way Forward
por: Ngum, Nancy, et al.
Publicado: (2022)

Industrial perceptions of medicines regulatory harmonization in the East African Community
por: Dansie, Live Storehagen, et al.
Publicado: (2019)

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017)

Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority: implications for African regulatory authorities
por: Danks, Lorraine, et al.
Publicado: (2023)

Corporate social responsibility of pharmaceutical industry in Korea
por: Bae, Green, et al.
Publicado: (2022)

Pharmaceutical Industry Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward
por: Sithole, Tariro, et al.
Publicado: (2022)

The New and Old Europe: East-West Split in Pharmaceutical Spending
por: Jakovljevic, Mihajlo, et al.
Publicado: (2016)

A practical approach to communicating benefit-risk decisions of medicines to stakeholders
por: Leong, James, et al.
Publicado: (2015)

The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making
por: Donelan, Ronan, et al.
Publicado: (2016)

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
por: Salek, Sam M., et al.
Publicado: (2019)

A Proposed Regulatory Review Model to Support the South African Health Products Regulatory Authority to Become a More Efficient and Effective Agency
por: Keyter, Andrea, et al.
Publicado: (2020)

Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication?
por: Keyter, Andrea, et al.
Publicado: (2020)

Future implications of ChatGPT in pharmaceutical industry: drug discovery and development
por: Zhao, Ailin, et al.
Publicado: (2023)

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
por: Rahalkar, Hasumati, et al.
Publicado: (2021)

The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges
por: Khan, Shahzadgai, et al.
Publicado: (2020)

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
por: Rahalkar, Hasumati, et al.
Publicado: (2018)

The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development
por: Reijntjes, Susan, et al.
Publicado: (2018)

Applications of Deep-Learning in Exploiting Large-Scale and Heterogeneous Compound Data in Industrial Pharmaceutical Research
por: David, Laurianne, et al.
Publicado: (2019)

Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges
por: Mundy, Charles, et al.
Publicado: (2023)

Evaluation of surveillance system for post market activities on pre-packaged foods in Greater Accra Region, Ghana, 2021
por: Osei Tutu, Benjamin, et al.
Publicado: (2022)

The socio-economic drivers of bushmeat consumption during the West African Ebola crisis
por: Ordaz-Németh, Isabel, et al.
Publicado: (2017)

Community-Level Pharmaceutical Interventions to Reduce the Risks of Polypharmacy in the Elderly: Overview of Systematic Reviews and Economic Evaluations
por: Soler, Orenzio, et al.
Publicado: (2019)

Needs‐driven talent and competency development for the next generation of regulatory scientists in Africa
por: Semete‐Makokotlela, Boitumelo, et al.
Publicado: (2021)

Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province
por: Matlala, Moliehi, et al.
Publicado: (2020)

Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure
por: Singh, Vijay K., et al.
Publicado: (2021)

Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities
por: Sithole, Tariro, et al.
Publicado: (2021)

Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Koyuncu, Oguzhan, et al.
Publicado: (2020)

The Regulatory Review Process in South Africa: Challenges and Opportunities for a New Improved System
por: Keyter, Andrea, et al.
Publicado: (2018)

Evaluating the Success of ZaZiBoNa, the Southern African Development Community Collaborative Medicines Registration Initiative
por: Sithole, Tariro, et al.
Publicado: (2020)

Best practices in the African Medicines Regulatory Harmonization initiative: Perspectives of regulators and medicines manufacturers
por: Ndomondo-Sigonda, Margareth, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6i3urmg7fvktpk0dtap43q1bbk